Page Therapeutics
6 employees on LinkedIn · 2 known investors
PAGE Therapeutics is an oncology drug development company developing compounds that disrupt cell-cell adhesion to dissolve circulating tumor cell (CTC) clusters and block cancer metastasis. Its lead work includes preclinical models and a proof-of-concept clinical trial in breast cancer patients.
Founders & leadership
NA
Nicola AcetoCo-founder & Chief Science Officer
CR
Christoph RochlitzCo-founder & Chief Medical Officer
DS
KV
Katharina VenturiChief Operating Officer
Investors · 2
Frequently asked questions
- What does Page Therapeutics do?
- PAGE Therapeutics is an oncology drug development company developing compounds that disrupt cell-cell adhesion to dissolve circulating tumor cell (CTC) clusters and block cancer metastasis. Its lead work includes preclinical models and a proof-of-concept clinical trial in breast cancer patients.
- Who founded Page Therapeutics?
- Page Therapeutics was founded by Nicola Aceto, Christoph Rochlitz.
- Who are Page Therapeutics's investors?
- Page Therapeutics's investors include Claris Ventures, XGEN Venture.